REN, renin, 5972

N. diseases: 721; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Kidney disease is an epidemic clinical problem causing significant morbidity and mortality, and current treatments are limited to renin-angiotensin system blockade or renal replacement therapy for the majority of affected individuals. 29605557 2018
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. 10081615 1999
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin genes in renal development and the occurrence and progression of renal diseases. 10192247 1999
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients. 21421655 2011
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin-aldosterone system inhibitors (RAASIs), including angiotensin-converting enzyme inhibitors, angiotensin AT1 receptor blockers and mineralocorticoid receptor antagonists (MRAs), are the cornerstone for the treatment of cardiovascular and renal diseases. 28541811 2017
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin-aldosterone system (RAAS) plays important roles in regulating renal hemodynamics and functions, as well as in the pathophysiology of hypertension and renal disease. 29600408 2018
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin-aldosterone system (RAAS) plays a central role in renal disease progression. 29882088 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin aldosterone system inhibitors are for a long time extensively used for the treatment of cardiovascular and renal diseases. 30681344 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin system inhibitors (RAS) drugs have a proteinuria-reducing effect that could prevent the progression of kidney disease in diabetic patients. 30817790 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin-aldosterone blockers have been known to have the benefits of delaying onset and progression of diabetic complications including nephropathy. 30864083 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. 31742881 2020
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE A novel REN gene mutation resulted in an alteration in the amino acid sequence of the renin signal sequence and caused childhood anemia, polyuria, and kidney disease. 21084044 2010
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Abbreviations BMI = body mass index BP = blood pressure CH = hypertensive crisis ContrHT = controlled hypertensive DBP = diastolic blood pressure GFR = glomerular filtration rate HbA1c = glycated hemoglobin HDLc = high-density lipoprotein cholesterol HE = hypertensive emergency HPLC = high-performance liquid chromatography HR = heart rate HU = hypertensive urgency JNC 7 = VII Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure LDLc = low-density lipoprotein cholesterol MDRD = Modification of Diet in Renal Disease NT = normotensive RASB = renin-angiotensin system blockers SBP = systolic blood pressure TC = total cholesterol TG = triglycerides. 28569557 2017
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Albuminuria is an early marker of kidney disease in patients with diabetes and/or hypertension undetected or untreated albuminuria is a leading cause of chronic kidney disease and cardiovascular events, The purpose of the present survey was to assess the prevalence of albuminuria in patients with diabetes and hypertension, treated with a combinations of renin angiotensin aldosterone system inhibitors and dihydropyridine calcium channel blockers. 30327190 2018
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 AlteredExpression group BEFREE Although the expression of renin and angiotensin-converting enzyme in experimental and human renal disease has been well characterized, no information is available regarding human angiotensin type 1 (AT1) receptor expression. 10073605 1999
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonstrating that RAAS inhibitors are superior to other antihypertensive drug classes in slowing nephropathy progression to end-stage renal disease. 29276100 2018
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease. 31425690 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE Angiotensin II, the most vasoactive component of the renin-angiotensin-aldosterone (RAAS) pathway, can contribute to renal disease by causing an increase in arterial blood pressure leading to glomerular injury and fibrosis. 18206321 2008
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Angiotensin-converting enzyme 2 (ACE2) is a recently described member of the renin-angiotensin system that hydrolyzes angiotensin (Ang) II to Ang-(1-7), and may thereby protect against cardiovascular and renal diseases. 28116710 2017
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Animal studies show that the renin-angiotensin system contributes to hypertension, glomerulosclerosis and progressive chronic renal failure in renal disease. 7700001 1994
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE As angiotensin II increases glomerular pressure, we studied the relationship between genetic polymorphisms in the renin-angiotensin system-angiotensin I converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II, subtype 1, receptor-and the renal involvement of insulin-dependent diabetic subjects with proliferative retinopathy: those exposed to the risk of nephropathy due to diabetes. 9120002 1997
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE As the intrarenal renin-angiotensin system might also be activated in this setting, we determined the ACE genotype together with other risk factors for the development of diabetic nephropathy in 122 patients with IDDM from a single centre with (n = 63) and without (n = 59) nephropathy. 9084972 1997
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 Biomarker group BEFREE Baseline data were used to describe patient characteristics and compare the adherence to ADA (American Diabetes Association) and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines with respect to metabolic and blood pressure control, use of renin-angiotensin system-blocking agents, statins and acetylsalicylic acid between the countries. 30238781 2019
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors and/or angiotensin II type 1 receptor blockers is the most effective treatment to achieve these purposes in non-diabetic and diabetic proteinuric renal diseases. 28482281 2017
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases
0.400 GeneticVariation group BEFREE Clinical and experimental studies that discuss the different immune functions of the renin-angiotensin system (RAS) in kidney diseases were reviewed, with emphasis on studies of kidney transplantation. 19539879 2009